The relationship between rat pharmacokinetics and physicochemical parameters [the partition coefficient between octanol and buffer at pH 7.4 (log D (7.4) ) and pK a ] was studied for a series of tetrahydropyran compounds. Sixteen compounds ranging in log D (7.4) 0.1 to 1.8 were administered intravenously to rats, and the pharmacokinetic parameters were determined from blood concentration time curves. Across the series, a weak correlation was observed between log D (7.4) and blood clearance, suggesting that log D (7.4) values less than 0.5 were required to prevent clearance at hepatic blood flow. In terms of the volume of distribution (V d ), the compounds fell into three distinct subseries characterized by the number of basic centers and differences in ionization of each basic center at physiological pH. These were referred to as the monobasic, weak second base, and strong second base subseries. All the compounds exhibited V d greater than body water, as would be expected from their lipophilic and basic nature. For a given clog P, the strong second base subseries showed higher V d than the weak second base subseries, which in turn exhibited higher values than the monobasic subseries. In addition, for the weak second base subseries, V d could be tuned by modulating the pK a of the second basic center. This relationship was rationalized in respect to the interactions of the ionizable centers with phospholipid heads in the cell membrane and/or lysosomal trapping. Compounds in the weak second base subseries showed optimal V d , and when combined with a log D (7.4) of 0.1, driving to moderate blood clearance, one compound showed the optimal pharmacokinetic profile.
The optimization of absorption, distribution, metabolism, and excretion properties and prediction of human pharmacokinetics have become important parts of the early selection process in drug discovery. It is well known that the physicochemical properties of a molecule (lipophilicity, molecular weight, hydrogen bonding potential, and pK a ) influence the pharmacokinetic profile of a molecule, and the desirable absorption, distribution, metabolism, and excretion properties have been defined (Smith, 2001; van De Waterbeemd et al., 2001) . In this article, we describe how the modulation of lipophilicity and pK a within a series of tetrahydropyran (THP) histamine type 3 receptor (H 3 ) antagonists was used to optimize rat pharmacokinetic parameters and to select an appropriate compound for further progression.
The objective of the H 3 antagonist program was to rapidly accelerate a candidate compound to proof-of-concept studies in allergic rhinitis. For the disease target in question, an orally administered compound with a once/twice-daily dosing regimen was key to development. Neither central nervous system penetration nor central nervous system exclusion was requisite in the candidate as the site of action was peripheral. In-house medicinal chemistry resulted in the identification of a number of potent H 3 antagonists containing a THP core ( Figs. 1 and 2 ).
This present report details the optimization of the pharmacokinetics within the THP series to identify a candidate for further progression. Key to the objectives was the identification of a compound with a predicted human half-life in the range of 12 to 30 h and an adequate oral bioavailability to allow a reasonably small dose (e.g., Ͻ50 mg).
Materials and Methods

Materials.
All the H 3 antagonists were synthesized by the Discovery Chemistry Department, Pfizer Global Research and Development (Sandwich, Kent, UK). All of the other chemicals and reagents, unless stated otherwise, were purchased from Sigma-Aldrich (St. Louis, MO). pK a Determination. An accurate measurement of the ionization constant values (pK a ) of the H 3 antagonists in a methanol-water binary mixture was performed by potentiometric titration. The potentiometric system consisted of a Sirius titrator GLpKa from Sirius Analytical Instruments Ltd. (Forest Row, East Sussex, UK) with combined electrode; the GLpKa instrument was supplied with Sirius pK a log P (the partition coefficient of a compound between octanol and water in its un-ionized form) software for the calculation of pK a . All of the measurements were carried out at constant temperature of 25°C, constant ionic strength of 0.15 M KCl (adjusted to pH 2 with 0.1 M HCl), and with a continuous flow of argon to prevent the absorption of CO 2 from the atmosphere. The solutions were then titrated with standardized KOH to pH 12. The apparent ionization constants, psK a , were obtained at each cosolvent solution by a weighted nonlinear least square procedure. The aqueous ionization constants, pK a 1 and pK a 2 , were obtained by Yasuda-Shedlovsky extrapolation of psK a values to 0% methanol (Gobry et al., 2000) .
Log D (7.4) Determination. The distribution coefficient of the H 3 antagonists between octan-1-ol and 0.1 M sodium phosphate buffer, pH 7.4, was determined by the shake flask methodology. This was completed in an automated manner with all the liquid handling performed on a Hamilton Microlab star (eight-probe) robot. Then, 0.3 mg of compound was dissolved in 300 l of octan-1-ol (pure; BDH, Poole, Dorset, UK) and aliquoted in duplicate into a 96-well block. Three hundred microliters of presaturated buffer (2 liters of buffer presaturated with 10 ml of octan-1-ol) was added to the wells, and the solution was vigorously mixed. After centrifugation, the two phases were separated. Ten microliters of a 1:200 dilution of the octan-1-ol layer and 10 l of a 1:20 dilution of the buffer layer were directly injected onto the highperformance liquid chromatography (HPLC) system described in full for the pharmacokinetic sample analysis. The peak areas were corrected for the dilution factors, and the following calculation was applied to determine the mean log D value at pH 7.4 (log D (7.4) ): LogD (7.4) ϭ log 10 (peak area for octan-1-ol samples) (peak area for buffer sample)
In Vitro Metabolism Studies in Rat and Human Liver Microsomes. The standard incubation mixture contained 50 mM potassium phosphate, pH 7.4, 5 mM MgCl 2 , 1 mM NADP ϩ , 5 mM isocitric acid, and 1 unit/ml isocitrate dehydrogenase (NADPH was generated in situ by the isocitric acid isocitrate dehydrogenase system). Both rat and human incubations were carried out at 1 M substrate concentration and 0.25 M cytochrome P450 concentration. Microsomes were purchased from BD Biosciences (Franklin Lakes, NJ) and were stored frozen in phosphate buffer at Ϫ80°C before use. Microsomal proteins were assayed by the method of Lowry et al. (1951) . The incubation mixture (without the NADP ϩ ) was incubated at 37°C for 20 min. NADP ϩ was then added to start the experiment. No cofactor and no drug controls were also prepared. Over a 60-min period, 9 ϫ 40-l aliquots were removed from the incubation mix and added to 100 l of ice-cold acetonitrile. A 10-l aliquot of 0.01 g/ml midazolam was added to each well for internal standardization purposes. The precipitated proteins were pelleted by centrifugation for 30 min at 1507g, and a 10-l aliquot of the supernatant was injected onto an HPLC system. This consisted of an OPTI-LYNX cartridge C18 column (15 ϫ 2.1 mm; Jay Tee Biosciences Ltd., Whitstable, Kent, UK) and an isocratic Jasco (Tokyo, Japan) pump pumping at 2 ml/min. The eluting mobile phase was 90% methanol, 10% water, 2 mM ammonium acetate, and 0.03% formic acid. Detection was by multiple reaction monitoring using a PerkinElmerSciex Instruments (Waltham, MA) API3000 triple quadrupole mass spectrometer. The extent of microsomal binding was estimated using an in-house in silico predictor. The intrinsic unbound clearance in vitro was calculated using the following equation adjusting the liver weight and concentration for the required species (Obach, 1997) :
Cl int ϭ 0.693 ϫ liver weight In vitro t 1/2 ϫ liver conc in incubation ϫ cF u(inc) Blood Binding Determination. Control blood was collected in-house, from male Sprague-Dawley rats and human volunteers, in potassium-EDTA tubes (Sarstedt, Inc., Newton, NC). Blood binding of the H 3 receptor antagonists was determined in vitro (n ϭ 6) by equilibrium dialysis (Spectrapor-1 dialysis membrane 6000 -8000 molecular weight cutoff; Spectrum, Laguna Hills, CA). One microgram of compound was added to 1 ml of rat/human blood and dialyzed against isotonic Krebs-Ringer buffer (1 ml, pH 7.4) for 4 h at 37°C. Six aliquots of 100 l were taken from the blood and buffer sides at the end of the dialysis experiment. They were extracted and analyzed by HPLC/mass spectrometry analysis as described for the rat pharmacokinetic samples. Blood binding values were determined using the following equation:
Single Intravenous Bolus Dose Rat Pharmacokinetic Dose Preparation. Compound was accurately weighed and dissolved in 5% dimethyl sulfoxide/ saline to give a final concentration of 1 mg/ml. Then, 1 ml/kg was dosed intravenously to each rat to give a final dose of 1 mg/kg. A dose check was performed at the end of the study, and data were only accepted if dose was within 20% of the initial concentration.
Animal Experimentation. Male Sprague-Dawley rats (Charles River UK, Margate, Kent, UK) selected at a weight of approximately 250 g were used.
Because rat pharmacokinetics were used in screening mode and only trends and gross differences between compounds were required, each compound was only dosed to n ϭ 1 rat. This increased speed, reduced compound requirements, and, most importantly, reduced the overall numbers of animals used for the study. Throughout the study, animals were housed in stock boxes with access to food and water ad libitum. Single doses were administered as an intravenous bolus via the tail vein. Over a 24-h period, blood (approximately 175 l) was sampled into heparin-coated tubes via a previously implanted in situ jugular vein cannula. The cannula was flushed with heparinized saline (10 units/ml) after each sample. All the blood samples were diluted 1:1 with distilled water and stored at 4°C before analysis. At all times, these studies were carried out in accordance with the requirements of the UK national legislation and conducted using the appropriate guidelines.
Analysis of Rat Blood Samples. Analyte was extracted from a 100-l aliquot of blood/water (1:1) following a liquid-liquid extraction technique. A volume of 10 l of a 1-g/ml solution of a structurally similar internal standard was added to each well. A volume of 1 ml of 0.1 M NaOH was added, and the samples were vortex-mixed. This was followed by a further 2 ml of ethyl acetate. Each sample was vortex-mixed for 30 s and centrifuged for 5 min at 1107g 4°C to separate the organic and inorganic layer. The organic layer was removed using a Pasteur pipette and transferred to a 96-well polypropylene block (Porvair Sciences Ltd., Leatherhead, Surrey, UK). Samples were evaporated to dryness under a nitrogen flow at 37°C and reconstituted in a volume of 300 l of mobile phase A, from which 180 l was injected onto the column. Chromatographic retention and separation were achieved on a Chromolith speed rod RP-18e 50 ϫ 4.6-mm column (OPTI-LYNX; Jay Tee Biosciences Ltd.). The column was maintained at ambient temperature, and the mobile phase flow rate was set at 3 ml/min with a 5:1 postcolumn split using a Jasco pump. The mobile phase composition was (A) 2 mM ammonium acetate in 90:10 methanol/water and 0.03% formic acid and (B) 40% 2 mM acetonitrile both containing 10:90 methanol/water and 0.03% formic acid 2% using a ballistic gradient. Under these conditions all the compounds were eluted at 2.5 Ϯ 0.5 min. The total run time injection to injection was 3.5 min. A PerkinElmerSciex Instruments API4000 with a turbo ion spray interface was used as the detector. Electrospray ionization using positive ion multiple reaction monitoring was the detection mode. Chromatograms were integrated using Analyst 1.4. software (Applied Biosystems, Foster City, CA), which was configured to automatically calculate and annotate the peak areas of both analyte and internal standard. Calibration curves were constructed using peak area ratios of the calibration samples and applying a 1/response (1/Y) weighted linear regression analysis. Analyte concentrations were calculated from the ratio of the analyte peak area to the internal standard peak area, interpolated from the calibration line.
Data Analysis. The following pharmacokinetic parameters were determined from individual animal data. dmd.aspetjournals.org the last time point using the linear trapezoidal rule and extrapolated to infinite time using the terminal elimination rate constant. Extrapolated AUC was Ͻ20% of 0 h to last time point AUC. 3. Clearance (Cl) was calculated by the relationship dose/AUC. 4. Volume of distribution (V d ) was calculated by the relationship Cl/K el . 5. Unbound volume of distribution (V du ) was calculated by dividing the total V d obtained from the intravenous pharmacokinetics by the free fraction of compound in the rat blood (van de Waterbeemd et al., 2001 ). 6. Unbound clearance (Cl u ) was calculated by dividing the total Cl obtained from the intravenous pharmacokinetics by the free fraction of compound in the rat blood (van de Waterbeemd et al., 2001) .
Results
Physicochemical Properties of the H 3 Antagonists. The structure and physiochemical properties of a subset of compounds from the THP series are shown in Table 1 and Fig. 2 . Many of the physicochemical properties are determined from computational models validated using algorithms and descriptors generated in-house (clog P, hydrogen bond acceptor, hydrogen bond donor). Compounds are basic (pK a Ͼ 6.5) and moderately lipophilic (clog P 1.8 -3.9 and log D 7.4 0.1-1.2) in nature containing either one or two basic centers. The molecular mass is less than 500 (318 -448), and they have a range of hydrogen bond donor and acceptor counts.
In Vitro Cytochrome P450 Metabolism of the H 3 Antagonists. The majority of the compounds assessed in vitro exhibited intrinsic Cl values of Ͻ7 l/min/mg protein in rat and human liver microsomes (Table 2 ) and low intrinsic Cl (Ͻ8 l/min/10 6 cells) in hepatocytes (data not shown). Where metabolism was observed in rat liver microsomes, the data were corrected for microsomal binding using an in silico predictor to determine the free fraction in the incubation mix (Hallifax and Houston, 2006 ).
Blood Binding of the H 3 Antagonists. The H 3 antagonists exhibited moderate blood binding values that translated to a free fraction in the blood ranging from 0.13 to 0.64. Individual values were used to calculate the rat Cl u values listed in Table 3 .
Intravenous Pharmacokinetics of the H 3 Antagonists in the Rat. The rat pharmacokinetic data of compounds in the THP series are summarized in Table 3 . A limitation of this study was the screening nature of the rat pharmacokinetic studies using one animal per time point. As discussed under Materials and Methods, this was believed appropriate because only trends and gross differences between compounds were to be considered.
In keeping with the basic nature of the series, all the compounds exhibited V d greater than that of body water. After an intravenous bolus dose of 1 mg/kg, compounds 1 through 3 containing one basic center at R1 displayed blood Cl values in excess of liver blood flow (Boxenbaum, 1980) . The half-life of these compounds was Յ1 h. Compounds 4 through 11 contain a second basic center at R2 that is partially ionized at physiological pH. The Cl of these compounds tended toward hepatic blood flow, and the V d ranged from 12 to 62 l/kg. Together these factors combined to give half-lives in the rat of 3 to 18 h. Compounds 12 through 16 contain two strongly basic centers, both of which are essentially fully ionized at physiological pH. The V d ranged from 30 to 99 l/kg, and the blood Cl values ranged from 5 to 32 ml/min/kg. The half-life values of these compounds ranged between 22 and 60 h.
Discussion
The objective of the H 3 antagonist program was to rapidly accelerate a first-in-class compound to proof-of-concept studies for the treatment of allergic rhinitis. Key to progression was the identification of a compound with a human half-life sufficiently long to minimize the variability in drug concentrations while providing exposure suitable for efficacy. The medicinal chemistry team identified the THP series in which H 3 potency and selectivity at the target were observed, in addition to chemical tractability. All the compounds were "rule of five"-compliant (Lipinski, 2000; Leeson and Springthorpe, 2007) ; therefore, adequate oral absorption was expected.
In general, the compounds were slowly metabolized by in vitro systems using rat and human liver microsomes (Table 2 ). These in vitro systems could not be used to select among compounds; therefore, the compounds were progressed to rat pharmacokinetic studies. In these studies, the compounds exhibited blood Cl values from 5 to 240 ml/min/kg. The lack of in vitro/in vivo correlation suggested that hepatic metabolism was not responsible for the observed in vivo Cl. The absence of unchanged compound in urine and bile (Pfizer inhouse data) suggested that renal and biliary elimination was also not a significant Cl pathway. Thus, the Cl pathway for this series of compounds remained unknown. It was rationalized that selection of compounds for further progression could be achieved based on scaling rat Cl to human using single species (assuming similar Cl pathways) and estimating human V d by accounting for protein binding differences between rat and human (Hosea et al., 2009) . The predicted human half-life was then calculated using t 1/2 ϭ (0.693 ⅐ V d )/Cl. Examination of blood Cl in rat across the whole series suggested a weak correlation with log D (7.4) (Fig. 3) .
In general, compounds at the higher end of the log D (7.4) range (i.e., Ͼ1) tended toward high Cl relative to hepatic blood flow. At the lower log D (7.4) range (Ͻ0.5), the Cl values were low to moderate with respect to hepatic blood flow. This empirical observation suggested that for this series, to be in an appropriate blood Cl range, a compound should possess a log D (7.4) of less than 0.5.
All the H 3 antagonist compounds studied exhibited V d significantly above body water (Table 3) . This was expected because all the compounds within the series contain at least one strongly basic center (Rodgers et al., 2005) and are lipophilic bases (van De Waterbeemd et al., 2001) .
Examination of the compound series with respect to ionization potential yielded some interesting observations. All the compounds contain one strongly basic center (pK a Ͼ 8.9). However, a number of compounds also contain a second basic center, ranging from weakly basic (pK a values 6.5-7.6) to strongly basic (pK a Ͼ 9.0). Thus, there were three potential subseries: monobasic, weak second base, and strong second base. The monobasic subseries (compounds 1-3) exhibited short elimination phase half-life values as a result of the combination of greater than hepatic blood flow Cl and moderate V d . In contrast, the elimination phase half-life values of the dibasic series were considered too long (22-60 h) in the rat to be suitable for once-daily dosing in humans. These values remained long despite attempts to modulate log P (to increase Cl of compounds 12-16) because Cl and V d changed similarly with log P.
In an attempt to identify a compound with ideal pharmacokinetic properties (low Cl, moderate V d , and moderate half-life), a strategy to maintain log D (7.4) less than 0.5 and modulate V d by altering the basicity of the second based center was used. Compounds 4 to 10 were synthesized with a second basic center ranging in pK a from 6.5 to 7.6. A positive correlation was observed between V du and the pKa of the weak second basic center (Fig. 4) . As a result a range of elimination half-lives was observed (3-18 h). This suggests that the V d of the weak second base subseries can be tuned by modulating the pK a of the second basic center. There are two potential explanations for this relationship (Fig. 5) . First, basic molecules are believed to express their tissue distribution through binding to the phospholipids that make up cell membranes (van De Waterbeemd et al., 2001) .
The membrane partitioning theory is based on the slightly acidic extracellular environment driven by the negative charges on the phospholipid head groups of the cell membrane. A monobasic compound with a pK a of 9.4 will be 99.9% ionized under these conditions (pH 6.4 used for illustration purposes). Tissue distribution for this base will be a combination of the electrostatic interaction of the positive charge with the negatively charged phospholipid heads, combined with lipophilic interactions with the triglyceride tails. The introduction of a second basic center introduces a second positive charge that potentially adds a further electrostatic interaction. The pK a of the second basic center will determine the extent of ionization at that center and therefore the extent of the second interaction. For example, under these conditions a second pK a of 6.4 will be 50% ionized; a pK a of 7.4 will be 90% ionized; and a pK a of 9.4 will be 99.9% ionized. If the degree of secondary interaction drives further tissue distribution, then it would be expected that the V d values would increase with increasing second pK a . The second potential mechanism to explain the observed V d relationship of these compounds is lysosomal trapping (de Duve et al., 1974; Daniel and Wójcikowski, 1997; Chanteux et al., 2003) . On entering into the lysosomal compartments within the cell, the pH changes to become a more acidic environment. Thus, the bases will be pushed toward a greater degree of ionization. Because only un-ionized molecules can partition across membranes, the rate of passive return to the blood will depend on the degree of ionization of the molecule, which in turn depends on the pK a relative to the pH within the lysosome. The monobasic compound with a pK a of 9.4 will be 99.99% ionized at this pH, with 0.01% present in the un-ionized form. The rate of partition of the un-ionized form back into the blood will determine the V d . The introduction of a second weak base (pK a 6.4 -7.4) will lower the amount of un-ionized molecules (i.e., only 1 or 10% of the 0.01% will be un-ionized) and should reduce the rate at which the compound can permeate back into the blood and thus increase the V d .
The contribution that lysosomal trapping makes to the distribution of molecules has been studied using an in situ perfusion of the isolated rat liver (Siebert et al., 2004) . These authors suggested that the hepatic distribution of atenolol (log P app 0.14) was mainly determined by lysosomal trapping, whereas for the more lipophilic propranolol (log P app 3.1) distribution was equally determined by lysosomal trapping and binding to membranes. Because the H 3 antagonists studied in this investigation exhibit clog P values greater than 1.8, membrane binding is likely to be a major contributor to their distributional behavior. This was further underlined by a series of tissue affinity experiments (data not shown). In summary, the H 3 antagonist subseries explored enabled the rational design of a compound with optimum pharmacokinetics. The monobasic series could be ruled out based on the observed liver blood flow Cl and moderate V d , leading to short elimination phase half-life values in the rat and poor oral bioavailability. The strong second base series was discounted based on rat pharmacokinetic parameters. These compounds tended toward moderate blood Cl and exhibited large V d . Consequently, the terminal elimination phase half-life values were long (Ͼ22 h). Extrapolation of the human pharmacokinetics of these compounds suggested the potential for acceptable oral bioavailability but with extremely long terminal elimination phase half-life values (Ͼ100 h). Pharmacokinetic profiles such as this are not ideal for compound development because such compounds take many doses to reach steady state. In addition, they add a level of complexity to clinical trials in terms of washout, reducing the feasibility of crossover designs, and are not easily withdrawn if a serious side effect becomes apparent.
For the third series with one strong and one weakly basic center, the V d were intermediate between the monobasic and the strong second base subseries. In this series, the acceptable Cl with respect to hepatic blood flow could be achieved by maintaining log D (7.4) less than 0.5, whereas the V d could be tuned through modulation of the pK a of the second basic center. Combined with a moderate V d , the predicted terminal elimination phase half-life would be acceptable for once-or twice-daily administration. The characteristics across the three series explored are best exemplified by compounds 1, 12, and 11 (Table 4) . Compound 11 was selected for further progression. 
